Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration

Table 1

Baseline characteristics before aflibercept initiation.

	Data (range)
Number of eyes	31
Number of patients, M/F	30, 9/21
Age (years)	70.1 ± 8.1 (60 to 86)
Length of previous anti-VEGF treatment (months)	41.3 ± 14.2 (15 to 58)
Average number of prior anti-VEGF injections	34.4 ± 11.9 (15 to 50)
Interval between the last anti-VEGF and aflibercept initiation (weeks)	4.9 ± 0.8 (4 to 6)
Status of the foveal IS/OS junction, disrupted/complete (%)	20/11 (65/35)

Values are mean ± SD unless otherwise indicated.
VEGF: vascular endothelial growth factor; IS/OS: inner/outer segment.